In a press release on November 16, 2020, Moderna announced their intended to submission to the FDA for Emergency Use Authorisation of their COVID-19 vaccine, on the back of their Phase 3 trial returning 94.5% efficacy. [1]
A fuller analysis was released on November 30, 2020, which showed a 94.1% efficacy.